



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi-110019(INDIA)

Tel.: 011 -47589500-51 (50
Lines)
Email.: info@medicamen.com
Web : www.medicamen.com
CIN
No.:L74899DL1993PLC056594

Ref: STEX/Results/Published-2020-21

Date: 16.08.2020

The BSE Ltd
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Company Number: 531146

Sub. : Copy of Publication for Un-Audited Financial Results for the Quarter ended June 30, 2020

Dear Sir,

The Board of Directors at their Meeting held on 13.08.2020 adopted the Un-Audited Financial Results of the Company for the quarter ended on June 30, 2020.

The copy of the results published in the Financial Express and Jansatta dated August 14, 2020 is enclosed.

This is for your information and records.

Thanking You,

Yours truly,

For Medicamen Biotech Limited

Sd/-
Parul Choudhary
Company Secretary

Encl: As above.



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi- 110019
(CIN: L74899DL1993PLC056594) Website: www.medicamen.com
Email id: cs@medicamen.com

Extracts of Un-Audited standalone & Consolidated Financial Results
for the Quarter ended on 30.06.2020

Sl. No.	Particulars	Standalone			Consolidated		
		Quarter Ended		Year Ended	Quarter Ended		Year Ended
		Un-Audited 30.06.2020	Un-Audited 30.06.2019	Audited 31.03.2020	Un-Audited 30.06.2020	Un-Audited 30.06.2019	Audited 31.03.2020
1	Total income from operations (net)	2619.93	3116.75	11925.09	2786.76	3116.75	12744.26
2	Net Profit/(Loss) for the period (before tax, exceptional and/or Extraordinary items)	305.27	431.77	1660.39	323.82	431.77	1798.02
3	Net Profit/(Loss) for the period before tax (after exceptional and/or Extraordinary items)	305.27	431.77	1660.39	323.82	431.77	1798.02
4	Net Profit/(Loss) for the period after tax (after exceptional and/or Extraordinary items)	210.49	328.13	1225.89	224.41	328.13	1329.12
5	Total comprehensive income for the period (Comprising Profit/(loss) for the period (after tax) and other Comprehensive income (after tax))	0.00	0.00	0.00	0.00	0.00	0.00
6	Equity Share Capital	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)						
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)						
	Basic:	1.72	2.75	10.09	1.84	2.75	10.94
	Diluted:	1.72	2.75	10.09	1.84	2.75	10.94

Note:

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on August 13, 2020.
- The figures are regrouped in previous year also, wherever considered necessary.
- The Company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per IND AS-33.
- Limited Review Report has been carried out by the Statutory Auditors for the above period.

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

Place: New Delhi
Date : 13.08.2020

HANA PHOSCHEM LIMITED

10, Basement, R.C. Vyas Colony, Bhillwara, 311001 Rajasthan
CIN:L24124RJ2004PLC019288,
Email: secretarial@krishnaphoschem.com Ph: 01482-237104, Fax: 01482-238638

NOTICE

Pursuant to Regulation 29 read with Regulation 47 of the Securities (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company will be held at 03:00 P.M. on 14.08.2020 at Registered Office at 5-O-20, Basement, R.C. Vyas Colony, and approve the unaudited financial results along with the limited review report for the quarter ended June 30, 2020.

The results are available on the website at <http://www.krishnaphoschem.com> and at <http://www.nseindia.com>.

By Order of the Board of Directors
For Krishna Phoschem Limited
Sd/-
(Priyanka Bansal)
Company Secretary

PRECISION ELECTRONICS LTD.

32104DL1979PLC009590
New Friends Colony, New Delhi - 110025

Financial Results for the Quarter Ended 30.06.2020

	Rs. In lakh			
	Quarter ended on 31.12.2019 Un-Audited	Quarter ended on 31.03.2020 Audited	Quarter ended on 30.06.2019 Un-Audited	Year ended on 31.03.2020
Total income from operations (net)	478	811	1,151	3,769
Net Profit/(Loss) before tax, (after exceptional and/or Extraordinary items)	3	(132)	55	39
Net Profit/(Loss) before tax (after exceptional and/or Extraordinary items)	3	(132)	55	39
Net Profit/(Loss) after tax (after exceptional and/or Extraordinary items)	2	(82)	41	45
Net Profit/(Loss) for the period after tax (after exceptional and/or Extraordinary items)	2	(73)	41	54
Total comprehensive income for the period (after tax) and other Comprehensive income (after tax)	1,385	1,385	1,385	1,385
Earnings Per Share (after tax) (after exceptional and/or Extraordinary items) (Basic)	0.01	(0.59)	0.30	0.32
(Diluted)	0.01	(0.59)	0.30	0.32

Detailed format of the Quarterly Financial Result as per Ind AS 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter ended June 30, 2020. The full format of the results is available on the BSE Ltd. website www.bseindia.com and www.pel-india.com.

The results of the Company for the first quarter ended 30th June, 2020, were approved by the Board of Directors at their meeting held on 20.08.2020. The Statutory Auditors of the Company have carried out their audit on the results.

On Behalf of the Board
For Precision Electronics Limited
Sd/-
ASHOK KUMAR KANODIA
Managing Director
DIN : 00002563

Mafatlal

MAFATLAL INDUSTRIES LIMITED

CIN: L17110GJ1913PLC000035
Regd. Office: 301-302, Heritage Horizon, 3rd Floor, Off: C.G. Road, Navrangpura, Ahmedabad-380 009. Tele. No. 079-26444404-06 Fax No. 079-26444403
E-mail : ahmedabad@mafatlals.com Web Site : www.mafatlals.com

To:
The Members,
Mafatlal Industries Limited

NOTICE OF 106th ANNUAL GENERAL MEETING, BOOK CLOSURE AND E-VOTING

NOTICE is hereby given that 106th Annual General Meeting (AGM) of the Company will be held on Thursday, the 10th September, 2020, at 12.30 P.M. through video conferencing or other audio-visual means (VC/OAVM), to transact the businesses, set out in the Notice dated 27th June, 2020 convening the said AGM. The Annual Report 2019-20, inter-alia containing the Notice of the said AGM, Directors Report, Auditors Report and Audited Financial Statements for the year ended 31st March, 2020 along with statement & disclosure annexed/attached thereto have been sent to the email ids of the shareholders whose e-mails were registered and is also posted on the website of the Company www.mafatlals.com

EXTRACT OF

Sl No	Particulars	STANDALONE			
		Quarter Ended 30.06.2020 (Un-Audited)	Previous Quarter Ended 31.03.2020 (Un-Audited)	Quarter Ended 30.06.2019 (Un-Audited)	Previous Year Ended 31.03.2020 (Audited)
	Total Income from Operations (net)	33.45	218.02	56.31	419.40
	Net Profit/(Loss) before tax (after exceptional and/or Extraordinary items)	39.95	(16.44)	(43.48)	(17.14)
1	Total Income from Operations (net)	29.56	(18.79)	(43.48)	(19.49)
2	Net Profit/(Loss) for the period (before Tax, Exceptional and other Comprehensive income and other Comprehensive income (after tax))	29.56	(18.79)	(43.48)	(19.49)
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	40.00	40.00	40.00	40.00
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	2,705.63	2,705.63	2,725.12	2,705.63
5	Total Comprehensive Income (Comprising Profit/(Loss) for the period (after tax) and other Comprehensive income (after tax))				

TRADE & INVESTMENT LIMITED

L55990DL1982PLC256291
Plot No. 39, RG Mall, Sector-9, Rohini, New Delhi-110085
Info@pptinvestment.com, Phone - 011-42804171, 9891442777

Financial Results for the Quarter Ended June 30, 2020

Sl No	Particulars	STANDALONE			
		Quarter Ended 30.06.2020 (Un-Audited)	Previous Quarter Ended 31.03.2020 (Un-Audited)	Quarter Ended 30.06.2019 (Un-Audited)	Previous Year Ended 31.03.2020 (Audited)
	Total Income from Operations (net)	33.45	218.02	56.31	419.40
	Net Profit/(Loss) before tax (after exceptional and/or Extraordinary items)	39.95	(16.44)	(43.48)	(17.14)
1	Total Income from Operations (net)	29.56	(18.79)	(43.48)	(19.49)
2	Net Profit/(Loss) for the period (before Tax, Exceptional and other Comprehensive income and other Comprehensive income (after tax))	29.56	(18.79)	(43.48)	(19.49)
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	40.00	40.00	40.00	40.00
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	2,705.63	2,705.63	2,725.12	2,705.63
5	Total Comprehensive Income (Comprising Profit/(Loss) for the period (after tax) and other Comprehensive income (after tax))				

meeting held on 13th August, 2020. The Stand out a Limited Review of aforesaid results.

PLACE: NOIDA
DATE: 13.08.2020

board
ited
Sd/
DIA
ctor
563

Place: Greater Noida, U.P.
Date: 13th August, 2020

For PG Electroplast Limited
Sd/
(Vishal Gupta)
Director

पंकज पीयूश ट्रेड एंड
CIN: L65990DL1

पंजीकृत कार्यालय: 314, 3रा तल, प्लॉट नं. 39 के समीप 85
वेबसाइट: www.pptinvestment.com, ईमेल: info@ppt42777
30 जून, 2020 को समाप्त तिमाही के लि

क्रम सं.	विवरण	समाप्त वर्ष 30.06.2020 (अनऑडिटेड)
1.	प्रचालनों से कुल आय (शुद्ध)	419.40
2.	कर से पूर्व सामान्य क्रियाकलापों से शुद्ध लाभ/(हानि)	17.14
3.	कर से बाद अवधि के लिए शुद्ध लाभ/(हानि) (असाधारण मदों के बाद)	19.49
4.	अवधि हेतु कुल व्यापक आय (अवधि हेतु (कर के बाद) लाभ/(हानि) एवं अन्य व्यापक आय (कर के बाद) से शामिल)	19.49
5.	प्रदत्त इक्विटी शेयर पूंजी	40.00
6.	आरक्षित (पूर्व वर्ष के अंकित तदन पत्र के अनुसार पुनर्मूल्यांकन आरक्षितों के अतिरिक्त)	705.63
7.	आय प्रति शेयर (असाधारण मदों से पूर्व एवं बाद) (₹. 10/- प्रति का)	
	मूल:	(4.87)
	तरल:	(4.87)

टिप्पणी:

- उपरोक्त परिणामों की ऑडिट कमिटी द्वारा समीक्षा की गई तथा 5 मंडल द्वारा अनुमोदित कर अभिलेख में लिये गये हैं। अ-संशोधित ऑडिट स्टॉक एक्सचेंज में दाखिल किया जा रहा है।
- इन परिणामों को कम्पनी अधिनियम, 2013 की धारा 133 के अंतर्गत 2015, कम्पनी (भारतीय लेखा मानक संशोधन) नियमावली, 2016 तदनुसार के अंतर्गत पहचान तथा मापन के सिद्धांतों के अनुसार तैयार किए गये हैं।
- अधिसूचना तिथि 25 मई, 2016 के माध्यम से सेबी द्वारा सेबी नियम, 2016 के अनुपालन में एतद्वारा हम घोषित करते हैं कि उपरोक्त ऑडिट नहीं किये गये हैं।
- पूर्व अवधि के आंकड़ों को चालू अवधि के वर्गीकरण के अनुरूप गये हैं।
- सेबी सर्कुलर CIR/EFDC/CMS/15/2015 तिथि 30 नवम्बर सेबी सर्कुलर तिथि 5 जुलाई, 2016, इंड ए एस तथा कम्पनी अधिनियम का अनुपालन करने वाले कम्पनियों के लिये लागू होता है, की अपेक्षा है।
- कोविड-19 महामारी के प्रसार से उल्लेखनीय गतिरोध तथा वैश्व प्रबंधन ने परिसम्पत्तियों की वसूली क्षमता/वाहक मूल्य पर महामारी के वैश्व आर्थिक स्थिति के भावी सूचकों के आधार पर प्रबंधन को परिलक्षित, प्रबंधन भविष्य की आर्थिक परिस्थितियों के किसी भी भौतिक परिवर्तनों को देखते हुए भविष्य में कम्पनी की परिसम्पत्तियों पर निर्णायक प्रभाव अंतर हो सकता है।

तिथि: 12 अगस्त, 2020
स्थान: नई दिल्ली

लिखित
स्ता./-
बंस
देशक



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi- 110019
(CIN: L74899DL1993PLC056594) Website: www.medicamen.com
Email id: cs@medicamen.com

**Extracts of Un-Audited standalone & Consolidated Financial Results
for the Quarter ended on 30.06.2020**

(In Lakhs)

Sl. No.	Particulars	Standalone			Consolidated		
		Quarter Ended	Year Ended	Quarter Ended	Year Ended	Year Ended	
		Un-Audited 30.06.2020	Un-Audited 30.06.2019	Audited 31.03.2020	Un-Audited 30.06.2020	Un-Audited 30.06.2019	Audited 31.03.2020
1	Total income from operations (net)	2619.93	3116.75	11925.09	2786.76	3116.75	12744.26
2	Net Profit/(Loss) for the period (before tax, exceptional and/or Extraordinary items)	305.27	431.77	1660.39	323.82	431.77	1798.02
3	Net Profit/(Loss) for the period before tax (after exceptional and/or Extraordinary items)	305.27	431.77	1660.39	323.82	431.77	1798.02
4	Net Profit/(Loss) for the period after tax (after exceptional and/or Extraordinary items)	210.49	328.13	1225.89	224.41	328.13	1329.12
5	Total comprehensive income for the period (Comprising Profit/(loss) for the period (after tax) and other Comprehensive income (after tax))	0.00	0.00	0.00	0.00	0.00	0.00
6	Equity Share Capital	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)						
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)						
	Basic:	1.72	2.75	10.09	1.84	2.75	10.94
	Diluted:	1.72	2.75	10.09	1.84	2.75	10.94

Note:

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on August 13, 2020.
- The figures are regrouped in previous year also, wherever considered necessary.
- The Company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per IND AS-33.
- Limited Review Report has been carried out by the Statutory Auditors for the above period.

Place: New Delhi
Date: 13.08.2020

For Medicamen Biotech Limited
Sd/
Rahul Bishnoi
Chairman